Shenyang Kangzhi Pharmaceutical Co., Ltd.

This product is a blood lipid regulating drug of clofibric acid derivatives. It reduces blood low-density lipoprotein, cholesterol and triglycerides by inhibiting the production of very low-density lipoprotein and triglycerides and increasing their catabolism at the same time; it also increases the production of apolipoprotein A1 and A11, thereby increasing high-density lipoprotein. This product also has the effect of reducing blood uric acid in normal people and patients with hyperuricemia. Animal experiments have shown that fenofibrate is teratogenic and carcinogenic.

This product is an antiviral drug. It has an inhibitory effect on herpes simplex virus, varicella zoster virus, cytomegalovirus, etc. in vitro. It inhibits viral replication by interfering with viral DNA polymerase and causing DNA chain extension interruption. This product has a special affinity for viruses, but has low toxicity to mammalian host cells.

This product is a macrolide antibiotic with the same mechanism of action as erythromycin and a similar antibacterial spectrum to erythromycin, but its antibacterial activity against most Gram-positive bacteria is slightly weaker. Some erythromycin-resistant Staphylococcus aureus are still sensitive to kitasamycin. This product also has considerable activity against diphtheria Corynebacterium, tetani Corynebacterium, gonorrhea Neisseria, pertussis Bordetella, Rickettsia and Chlamydia trachomatis.

Sedative and hypnotic, protect heart rhythm, prolong the sleep time of animals with sodium pentobarbital, tolerate hypoxia, promote the phagocytic function of mononuclear phagocytes, and have a protective effect on arrhythmias caused by aconitine

Non-addictive antitussive drugs can inhibit the cough center, inhibit the pulmonary vagus nerve reflex caused by lung and pleural stretch receptors, and relax bronchial smooth muscles. That is, it has both central and peripheral antitussive mechanisms.